報價延遲最少15分鐘:2026/03/23 13:50 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.68 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.60/-0.24
|
|
企業價值
2.04B
|
| 資產負債 |
|
每股賬面淨值
6.47
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
460.16M
|
|
每股收益
2.35
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others. |
